(Corrects headline and first paragraph to show that Daxas rights were returned to Takeda.)
Jan. 25 (Bloomberg) -- Takeda Pharmaceutical Co.’s Daxas lung drug failed to win the backing of the U.K.’s health-cost agency in final guidance on the treatment of severe chronic obstructive pulmonary disease.
The drug, also known as roflumilast, is most likely to be used in addition to triple therapy, but there wasn’t direct clinical evidence to the product’s use in that way, the National Institute for Health and Clinical Excellence said in an e-mailed statement. The agency repeated its recommendation to conduct a trial of Daxas in combination with other commonly used treatments to prove the drug offers an advantage.
Merck & Co. last month ended its agreement with Japan’s Takeda to promote the drug in certain European countries and Canada.
To contact the reporter on this story: Kristen Hallam in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com